Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder

Children's Oncology Group60 enrolled

Overview

RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn about changes that occur in RNA and identify biomarkers related to cancer. PURPOSE: This research trial studies RNA samples from patients with Down syndrome and acute myeloid leukemia or other transient myeloproliferative disorder.

OBJECTIVES: * To compare miRNA expression in distinctive diagnostic groups: transient myeloproliferative disorder (TMD), Down syndrome (DS) acute megakaryocytic leukemia (AMkL), non-DS AMkL, and in remission DS samples (representing germline, non-malignant samples). OUTLINE: Archived RNA samples are analyzed for mature micro (mi)RNA expression by real-time RT-PCR. Results are then compared with miRNA expression of non-Down syndrome patients with acute megakaryocytic leukemia.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Leukemia

Interventions

RNA analysisGENETIC

reverse transcriptase-polymerase chain reactionGENETIC

laboratory biomarker analysisOTHER

Eligibility

Sex: ALLMax age: 3 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Patients with Down syndrome (DS) diagnosed with acute myeloid leukemia or transient myeloproliferative disorder * Clinical samples obtained from patients enrolled on the COG AAML0431 and COG AAML08B1 PATIENT CHARACTERISTICS: * Previously consented to biologic studies PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Outcomes

Primary Outcomes

Gene expression levels between DS AMKL and non-DS AMKL patients

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.